Codes, secret

The French text reads as follows En particulier, les navires-hopitaux ne pourront posseder ni utiliser de code secret pour leurs emissions par T.S.F. ou par tout autre moyen de communication. T.S.F stands for transmission sans fil , i.e. wireless , and emissions for transmission or broadcast . 

Geheimnis, /. secret, secrecy, mystery, geheimnisvoll, a. mysterious, mystic, occult. Geheim-rat, m, privy councilor, -schrift, /. secret writing, code, cipher, -tinte, /. invisible ink. 

Overexpression of apoaequorin (Inouye et al., 1989, 1991). To produce a large quantity of apoaequorin, an apoaequorin expression plasmid piP-HE containing the signal peptide coding sequence of the outer membrane protein A (ompA) of E. coli (Fig. 4.1.12) was constructed and expressed in E. coli. The expressed apoaequorin was secreted into the periplasmic space of bacterial cells and culture medium. The cleaving of ompA took place during secretion thus the... 

Tyson, Donald. The power of the word - the secret code of creation.. ... 

His name has become a synonym for clairvoyance Nostradamus, astrologer to the king of France, the most famous seer in Western history. But the real meaning of his prophecies has gone undetected, hidden in a secret alchemical code. Known as the Green Language, it was understood by only a handful of medieval occult scholars, and has been lost for centuries — until now... 

Several other C-type lectins have since been found in Toxocara (Fig. 12.4). Two are simple variants of TES-32, differing by 13-17% in amino acid sequence but with identical ligand binding sites these have been termed CTL-2 and CTL-3. It has yet to be determined whether these additional lectins are alleles or represent different coding loci, and it has not been established whether they are also secreted. A fourth lectin, CTL-4, corresponds to TES-70 (Loukas et al, 2000), as described below. In addition, there is some evidence that TES-45 and TES-55 are lectins, as detailed below. 

In cells that synthesize epinephrine, the final step in the pathway is catalyzed by the enzyme phenylethanolamine /V-methyltransferase. This enzyme is found in a small group of neurons in the brainstem that use epinephrine as their neurotransmitter and in the adrenal medullary cells, for which epinephrine is the primary hormone secreted. Phenylethanolamine N-methyltransferase (PNMT) transfers a methyl group from S-adenosylmethionine to the nitrogen of norepinephrine, forming a secondary amine [5]. The coding sequence of bovine PNMT is contained in a... 

Sun, L. and Muller-Schwarze, D. (1998) Anal gland secretion codes for family membership in the beaver. Behav. Ecol. Sociobiol. 44, 199-208. 

Process Safety Review Procedures for Capital Projects Process and Equipment Integrity Human Factors Company Standards, Codes, and Regulation Employee Participation Pre-Startup Safety Review Mechanical Integrity Hot Work Permit Emergency Planning and Response Trade Secrets Planning for Emergencies... 

As would be expected of active protein secreting cells, glandular epithelial tissue, the cytokine secreting cells of the immune system and the blood vessel endothelium, have an extensive internal structure consisting of rough endoplasmic reticulum and numerous mitochondria. Peptide hormones, growth factors and cytokines like all proteins are synthesized by DNA transcription and mRNA translation. The primary transcript of the mRNA may code for an inactive prohormone which requires careful proteolysis to produce the active hormone, as for example in the case of insulin. Adrenocorticotropic hormone (ACTH) is particularly interesting in this respect because... 

In sharp contrast, in trade secrets each state has its own law. Historically, this law is derived primarily from judicial interpretation of the English common law. Some states use the Code Napoleon or Spanish law as a background. As set forth in Stamicarbon N.V. vs. American Cyanamid Co. (3), no fewer than 20 states during the past nine years have enacted statues making appropriation or unauthorized disclosure of trade secrets a crime. The decision lists the states. One commendable statute is that in New Jersey (4). 

The Code of Professional Responsibility of the American Bar Association, Disciplinary Rule 2-108, provides in part that a lawyer shall not be a party to or participate in a partnership or employment agreement with another lawyer that restricts the right of a lawyer to practice law after the termination of a relationship created by the agreement, except as a condition to payment of retirement benefits. DR 4-101 provides for the protection of confidences and secrets of a client presumably forever unless disclosure is necessary under conditions set forth in the fine print, as, for example, to collect his fee. Interestingly, DR 2-106 (B) (2) provides that the determination of a reasonable fee includes "the likelihood, if apparent to the client, that the acceptance of the particular employment will preclude other employment by the lawyer. A lawyer cannot serve both sides in a dispute, and taking one client may later bar lucrative employment. 

The treatment of nonpatentable secret processes is not covered by any one specific statutory code section as in the case of patents, but it is governed by all the rules generally applicable to capital transactions. While you can t confidently predict results in this area, it is possible to get capital gain treatment from the sale of a nonpatentable secret process. Such a result could very possibly be challenged by the IRS on the grounds that the transaction is a license or that the secret process is not a capital asset. 

Chimeric antibodies can be expressed in mammalian cells by introducing the recombinant DNA that codes for the antibody into the cells and selecting for the rare cell that has integrated the DNA into its own chromosomes and then expresses a new protein — the desired antibody. Additional genetic manipulations of the mammalian cells are then required to select cells that secrete large amounts of the recombinant protein. Following this research and development model would theoretically lead to successful monoclonal therapies, but in practice, it had never been accomplished before the IDEC team developed rituximab. 

The first two antibodies our group tried to express in this vector system within mammalian cells had mistakes in the genetic material that coded for variable regions and, consequently, did not express any antibody at all. The first antibody that was produced by recombinant technology at IDEC using this vector system was in early 1991. It was supposed to be a chimeric anti-CD4 antibody, but the antibody secreted by the cells did not bind to CD4. CD4 is a surface molecule on the leukocytes known as T cells. A primatized antibody (a chimeric antibody where the variable domains are isolated from a cynomol-gus monkey see Figure 32.2) to CD4 was produced later that year. That antibody ended up in clinical trials in humans at the same time as Rituxan. 

---